These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30480878)

  • 1. Platelet miR-28 expression level and thrombocytosis in MPN patients.
    Stolyar MA; Gorbenko AS; Olkhovskiy IA
    Int J Lab Hematol; 2019 Apr; 41(2):e43-e45. PubMed ID: 30480878
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of myeloproliferative neoplasms.
    Skoda RC; Duek A; Grisouard J
    Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
    Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
    Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
    [No Abstract]   [Full Text] [Related]  

  • 5. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transcription factor NFE2 enhances expression of the hematopoietic master regulators SCL/TAL1 and GATA2.
    Siegwart LC; Schwemmers S; Wehrle J; Koellerer C; Seeger T; Gründer A; Pahl HL
    Exp Hematol; 2020 Jul; 87():42-47.e1. PubMed ID: 32593672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZBTB44-FLT3 fusion in a patient with a myeloproliferative neoplasm.
    Zhou X; Yang C; Zou Z; Lang X; Chen P; Chen S; Wang K; Chen Y; Hao Y; Chen N; Ding J; Li Y; Shen Y; Xiao S
    Br J Haematol; 2020 Oct; 191(2):297-301. PubMed ID: 32866288
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet phospholipids in thrombocytosis due to myeloproliferative disorders.
    Breuer JH; Harsányi V; Solti V; Hollán SR
    Haemostasis; 1981; 10(3):134-40. PubMed ID: 7262643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.
    Hu AY; Zhou T
    Br J Haematol; 2019 Jan; 184(1):8. PubMed ID: 30407632
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).
    Visconte V; Tabarroki A; Zhang L; Hasrouni E; Gerace C; Frum R; Ai J; Advani AS; Duong HK; Kalaycio M; Saunthararajah Y; Sekeres MA; His ED; Shetty S; Rogers HJ; Tiu RV
    Am J Hematol; 2014 Aug; 89(8):862. PubMed ID: 24796269
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Notch disruption on myeloid development.
    Francis OL; Chaudhry KK; Lamprecht T; Klco JM
    Blood Cancer J; 2017 Aug; 7(8):e598. PubMed ID: 28841212
    [No Abstract]   [Full Text] [Related]  

  • 12. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis.
    Clezardin P; McGregor JL; Dechavanne M; Clemetson KJ
    Br J Haematol; 1985 Jun; 60(2):331-44. PubMed ID: 4005182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micronuclei, dmin chromosomes and MYC amplifications as a singular presentation of myeloid malignancies.
    Montoro MJ; Rivero E; Teixidó M; Rodriguez Y; Chávez C; Salamero O; Navarrete M; Talavera E; Ortega M; Valcárcel D
    Br J Haematol; 2020 Oct; 191(1):e19-e22. PubMed ID: 32627175
    [No Abstract]   [Full Text] [Related]  

  • 15. Preliminary investigation about the expression of tubulin in platelets from patients with iron deficiency anemia and thrombocytosis.
    Yung KC; Zhang ZW; Yu WJ; Qiu JF; Xu CW; He CL; Xu XR; Yin J
    Hematology; 2018 Sep; 23(8):549-557. PubMed ID: 29499633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant calreticulin: when a chaperone becomes intrusive.
    Cazzola M
    Blood; 2016 Mar; 127(10):1219-21. PubMed ID: 26965919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
    Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
    PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal and malignant megakaryopoiesis.
    Wen Q; Goldenson B; Crispino JD
    Expert Rev Mol Med; 2011 Oct; 13():e32. PubMed ID: 22018018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
    Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
    J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZBTB7A links tumor metabolism to myeloid differentiation.
    Redondo Monte E; Kerbs P; Greif PA
    Exp Hematol; 2020 Jul; 87():20-24.e1. PubMed ID: 32525064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.